bioAffinity Technologies, Inc.
BIAF
$10.50
$1.5717.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.90M | 5.66M | 6.16M | 6.78M | 7.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.90M | 5.66M | 6.16M | 6.78M | 7.68M |
| Cost of Revenue | 3.86M | 3.79M | 4.23M | 4.89M | 5.39M |
| Gross Profit | 2.04M | 1.87M | 1.94M | 1.89M | 2.29M |
| SG&A Expenses | 11.35M | 10.70M | 9.91M | 9.80M | 9.95M |
| Depreciation & Amortization | 413.20K | 464.80K | 504.90K | 534.80K | 572.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.28M | 17.22M | 16.73M | 17.16M | 17.74M |
| Operating Income | -12.38M | -11.56M | -10.57M | -10.38M | -10.06M |
| Income Before Tax | -15.18M | -15.84M | -14.87M | -14.70M | -11.65M |
| Income Tax Expenses | 6.40K | 35.40K | 44.10K | 40.90K | 40.30K |
| Earnings from Continuing Operations | -15.19 | -15.88 | -14.91 | -14.74 | -11.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.19M | -15.88M | -14.91M | -14.74M | -11.69M |
| EBIT | -12.38M | -11.56M | -10.57M | -10.38M | -10.06M |
| EBITDA | -11.97M | -11.10M | -10.07M | -9.85M | -9.49M |
| EPS Basic | -103.36 | -169.77 | -231.31 | -310.99 | -312.62 |
| Normalized Basic EPS | -64.56 | -105.73 | -144.04 | -193.85 | -194.84 |
| EPS Diluted | -103.36 | -169.77 | -231.31 | -310.99 | -312.62 |
| Normalized Diluted EPS | -64.56 | -105.73 | -144.04 | -193.85 | -194.84 |
| Average Basic Shares Outstanding | 1.02M | 722.20K | 458.60K | 193.50K | 149.90K |
| Average Diluted Shares Outstanding | 1.02M | 722.20K | 458.60K | 193.50K | 149.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |